Analyst Ratings For Legend Biotech
Portfolio Pulse from Benzinga Insights
Analyst ratings for Legend Biotech (NASDAQ:LEGN) show a diverse range of opinions, with recent updates indicating a shift towards more bullish sentiments. The average 12-month price target for LEGN has been raised to $84.25, marking an 8.01% increase from the previous target of $78.00. Legend Biotech, a clinical-stage biopharmaceutical company, has shown significant revenue growth of 187.57% as of December 31, 2023, outperforming peers in the Health Care sector. However, the company faces challenges with a net margin of -182.24% and below-average ROE and ROA, indicating potential profitability and asset utilization issues.
April 17, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech has seen a positive shift in analyst sentiment, with an increased average price target of $84.25. The company's significant revenue growth contrasts with its profitability challenges, as indicated by its negative net margin and below-average ROE and ROA.
The increase in the average price target and the recent bullish sentiment from analysts suggest a positive short-term outlook for LEGN's stock price. However, investors should be cautious of the company's profitability issues, which could impact long-term performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100